KIT and gastrointestinal stromal tumor: Following this approach will provide significant insight into the cargo of in vivo huMC EVs and the opportunity to compare the content of huMC EVs under normal and diseased conditions, with a potential use as biomarkers of specific pathology, as also proposed in a study analyzing KIT‐containing exosomes from patients with GIST before and after treatment with tryosine kinase inhibitors (Atay et al., 2018).